Skip to main content

Table 1 Participant characteristics by experimental group

From: Bulk RNA sequencing for analysis of post COVID-19 condition in adolescents and young adults

 

Group

 

SARS + /F + (n = 20)

SARS + /F- (n = 20)

SARS-/F + (n = 20)

SARS-/F- (n = 20)

Time since symptom onset/PCR test

(days, median (IQR))

212 (12)

213 (12)

211 (15)

215 (13)

Demographic characteristics

    

 Sex (female, %))

20 (100)

20 (100)

20 (100)

20 (100)

 Age (median (IQR))

21 (7)

19 (7)

19 (3)

19 (5)

 BMI (median (IQR))

21 (6)

21 (4)

23 (6)

23 (4)

 Ethnicity (European (%))

14 (70)

15 (75)

20 (100)

20 (100)

 Current comorbidity (any (%))

2 (10)

0 (0)

3 (15)

0 (0)

 COVID-19 immunization (yes (%))

15 (75)

14 (70)

18 (90)

19 (95)

Symptoms and functional impairment scoresa

    

 Fatigueb (score 0–33, mean (SD))

25 (3)

10 (2)

17 (3)

11 (2)

 Post exertional malaisec (score 0–100, median (IQR))

73 (26)

0 (5)

23 (23)

0 (6)

 Cognitive symptomsd (range 3–15, median (IQR)

13 (3)

3.5 (2)

8.5 (5)

4.5 (2)

 Respiratory symptomse (range 2–10, median (IQR))

5 (2.3)

3 (1)

3 (1)

3 (1)

 Symptoms of anxietyf (range 0–21, median (IQR))

10 (6.5)

4 (3.5)

9 (5.3)

4 (3.3)

 Symptoms of depressiong (range 0–21, median (IQR))

7 (4.3)

1.5 (2.5)

3.5 (6)

1 (2.3)

 Quality of lifeh (range 0–100, median (IQR))

49 (12)

89 (7.6)

70 (15)

87 (11)

Laboratory findings

    

 Hemoglobin g/dL (mean, SD)

12.73 (0.56)

12.7 (1.50)

13.52 (0.87)

13.42 (0.55)

 Leukocyte count, 109 cells/L (mean, SD)

6.5 (1.7)

6.4 (2.2)

6 (1.6)

5.8 (1.5)

 hsCRP (plasma, mg/L, median (IQR))

0.8 (0.9)

1.1 (1.1)

2.4 (5.0)

3.5 (4.9)

 IP10 (plasma, pg/mL, median (IQR))

124 (56)

112 (78)

98 (70)

91 (77)

 Eotaxin (plamsa, pg/mL, median (IQR))

14.2 (4.1)

13.9 (3.8)

11.3 (3.9)

10.1 (6.0)

 MCP-1 (plasma, pg/mL, median. (IQR))

4.6 (3.2)

5.2 (3.1)

3.0 (2.7)

1.9 (4.9)

 SARS-CoV-2 antibody titeri

22 (23)

17 (56)

0.1 (0)

0.1 (0)

  1. BMI body mass index; MCP monocyte chemotactic protein; IP interferon gamma induced protein; hsCRP high-sensitive assay of C-reactive protein; PCR polymerase chain reaction
  2. awith the exception of quality of life, higher values imply more symptoms. For quality of life, higher values imply higher quality of life and less functional impairment
  3. bFrom the Chalder Fatigue Questionnaire
  4. cFrom the DePaul Symptom Questionnaire
  5. dThe sum score across the 3 items memory problems, concentration problems, and decision-making problems
  6. eThe sum of scores across dyspnea and coughing
  7. fFrom the Hospital Anxiety and Depression Scale anxiety subscale
  8. gFrom the Hospital Anxiety and Depression Scale depression subscale
  9. hFrom the Pediatric Quality of Life Inventory
  10. iTotal antinucleocapsid immunoglobulin G and M
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us